QKV · Electromechanical Tear Stimulator
Ophthalmic · 21 CFR 886.5305 · Class 2
Overview
| Product Code | QKV |
|---|---|
| Device Name | Electromechanical Tear Stimulator |
| Regulation | 21 CFR 886.5305 |
| Device Class | Class 2 |
| Review Panel | Ophthalmic |
Identification
An electromechanical tear stimulator is a non-implantable device intended to increase tear production via mechanical stimulation.
Classification Rationale
Class II (special controls). The special controls for this device are:
Special Controls
In combination with the general controls of the FD&C Act, the electromechanical tear stimulator is subject to the following special controls:
*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing under anticipated conditions of use must evaluate tear production and all adverse events, including tissue damage, pain, headache, and discomfort. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following must be conducted: (i) An assessment of mechanical output specifications, including vibration amplitude and frequency, pressure and force, and acoustic (noise level) properties; (ii) Mechanical safety testing to validate safeguards related to the pressure aspects of the device; and (iii) Use life testing. (3) Performance data must demonstrate the electrical safety, thermal safety, and electromagnetic compatibility (EMC) of all electrical components of the device. (4) All patient-contacting components of the device must be demonstrated to be biocompatible. (5) Software verification, validation, and hazard analysis must be performed. (6) Physician and patient labeling must include: (i) A detailed summary of the device's technical parameters; (ii) Instructions for use, including an explanation of all user-interface components and information regarding proper device placement; (iii) Information related to electromagnetic compatibility classification; (iv) Instructions on how to clean and maintain the device; (v) A summary of the clinical performance testing conducted with the device; (vi) Language to direct end users to contact the device manufacturer and MedWatch if they experience any adverse events with this device; and (vii) Information on how the device operates and the typical sensations experienced during treatment.
Cleared Devices (2)
| Record | Device Name | Applicant | Decision Date | Decision |
|---|---|---|---|---|
| K213623 | iTEAR100 Neurostimulator | Olympic Ophthalmics | Mar 16, 2022 | SESE |
| DEN190026 | iTEAR Neurostimulator | Olympic Ophthalmics, Inc. | May 1, 2020 | DENG |
Top Applicants
- Olympic Ophthalmics, Inc. — 1 clearance
- Olympic Ophthalmics — 1 clearance